PharmaJet, the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL, the maker of Afluria (influenza vaccine) on Tuesday announced the Food and Drug Administration has approved the PharmaJet Stratis 0.5mL Needle-Free Jet Injector for delivery of Afluria in individuals ages 18 years to 64 years.
According to a report from the American Academy of Family Physicians, the Advisory Committee on Immunization Practices for the Centers for Disease Control and Prevention voted unanimously to recommend that healthy children between the ages of 2 years and 8 years be inoculated with a live attenuated influenza vaccine like FluMist, as opposed to the traditional flu shot.
The Advisory Committee on Immunization Practices on Wednesday voted to recommend a preference for using the nasal spray flu vaccine instead of the flu shot in healthy children ages 2 years to 8 years of age when it is immediately available.
AstraZeneca on Tuesday announced the Food and Drug Administration approved Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).
NEW YORK — New Albertsons Inc. banners Shaw’s and Star Market, Acme and Jewel-Osco have announced the availability of flu shots at their pharmacies.
Specially trained pharmacists are available to administer the traditional flu vaccine, needle-free FluMist nasal spray and Fluzone Intradermal, as well as Fluzone HD for patients ages 65 years and older during regular pharmacy hours with no appointment necessary.
The Centers for Disease Control and Prevention set the stage for the first quadrivalent influenza vaccine to be introduced in the 2013-2014 flu season, according to a report in The Wall Street Journal.
The Food and Drug Administration on Wednesday approved Protein Sciences' Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology.
Amid an unusually strong flu season that the Centers for Disease Control and Prevention has called an epidemic, supplies of flu vaccines are running low, and some people hoping to get immunized are having trouble finding them.
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate’s pandemic influenza vaccine candidate in the United States.